Cerebral MRI abnormalities associated with vigabatrin therapy.
about
Optimal management of seizures associated with tuberous sclerosis complex: current and emerging optionsDisorders of GABA metabolism: SSADH and GABA-transaminase deficienciesIn-vivo multi-exponential T2, magnetization transfer and quantitative histology in a rat model of intramyelinic edema.Bilateral symmetrical basal ganglia and thalamic lesions in children: an update (2015).A case of acute onset succinic semialdehyde dehydrogenase deficiency: neuroimaging findings and literature review.Magnetic resonance imaging patterns of treatment-related toxicity in the pediatric brain: an update and review of the literature.Succinic semialdehyde dehydrogenase deficiency: lessons from mice and menMedication neurotoxicity in children.Non-vision adverse events with vigabatrin therapy.Safety and tolerability of antiepileptic drug treatment in children with epilepsy.An investigation into the relationship between vigabatrin, movement disorders, and brain magnetic resonance imaging abnormalities in children with infantile spasms.Thirty years beyond discovery--clinical trials in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism.Safety and efficacy of vigabatrin for the treatment of infantile spasms.Quantitative magnetic resonance imaging evidence for altered structural remodeling of the temporal lobe in West syndromeEvaluating risks for vigabatrin treatmentTreatment of refractory complex partial seizures: role of vigabatrin.Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval.Infantile spasms: a U.S. consensus report.Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms.Vigabatrin for infantile spasms.Balancing clinical benefits of vigabatrin with its associated risk of vision loss.Vigabatrin monotherapy for infantile spasms.Latest American and European updates on infantile spasms.The long-term safety of antiepileptic drugs.Recent advances in the pharmacotherapy of infantile spasms.Vigabatrin's complicated journey--to be or not to be?Improving Outcomes in Infantile Spasms: Role of Pharmacotherapy.Risk of vigabatrin-associated brain abnormalities on MRI in the treatment of infantile spasms is dose-dependent.Lesions in the Splenium of the Corpus Callosum on MRI in Children: A Review.Pathological evidence of vacuolar myelinopathy in a child following vigabatrin administration.West Syndrome: A Review and Guide for Paediatricians.A novel mutation of ALDH5A1 gene associated with succinic semialdehyde dehydrogenase deficiency.Treatment of West syndrome with vigabatrin: reversible MRI signal changes.T2 hyperintense signal of the central tegmental tracts in children: disease or normal maturational process?Homozygous mutation in PRUNE1 in an Oji-Cree male with a complex neurological phenotype.Clinical findings in a patient with FARS2 mutations and early-infantile-encephalopathy with epilepsy.
P2860
Q22305852-F5CAA135-EA16-4FCF-9C9D-406552F97E74Q28253528-09D18E42-EDAF-4B2D-9D37-47546F9D97EBQ30687567-1BD5DC38-2A38-4113-8DC5-65ABA9746805Q30984026-4B132841-126B-442C-927B-4D9ED8C5F378Q31010741-77EB4E62-06ED-4090-A87A-584BF14824B2Q31147678-F39E6C4C-FC67-452E-9F0C-3AB4797D5552Q33403217-A4DF1A8E-84BA-45CA-91D0-353C04B0015FQ33970034-58818BB4-3824-4314-9D4F-8B82BB4F0EFDQ34068916-CA073258-CC24-48CB-B256-508DFF6A3463Q34281872-6814184C-D9CE-4B96-8371-6DB7E0C30C65Q34780400-B187CA90-3F54-4EC7-AB55-833864E1F1E1Q35146643-F8301978-56A9-4C78-A48F-8E35DBF2713FQ36873912-50CEA4FF-E0C1-46E4-8F64-B64900778120Q37222016-5051EDC5-1E59-451A-8016-CE8AB9257F80Q37380373-BB6CC238-3539-4BE9-BB9B-B190013F7EC1Q37620193-CA7472C1-F659-4BED-85D6-2A6CDE3AF7E1Q37642768-4F6A47A7-301D-4E7F-9995-08E46E306BFEQ37770587-DA57FF9A-55EC-4FE7-A05F-AAA8295A1EB5Q37815377-7C07109E-F915-4990-86D0-A7AC233CDC46Q37848404-8EEEA973-F3B2-4EC7-AEF5-A2E3120BE9B9Q37953583-07436201-585C-45EE-AA4E-4883196F0FAEQ37987986-10751735-C07D-4168-9B0E-B4ED16D63B9EQ38076086-95877931-22CB-45EF-92C7-9E050461FA3DQ38106856-C69DCD48-2689-4DDA-AFDB-48EED1C982ADQ38185985-EB425040-254A-498C-8D3C-6DB71CF54AB0Q38570933-76BF351B-FBCF-4658-A2CA-9F75E43EE250Q38931988-72D699DB-1609-4994-BE8D-0E09A006CB2EQ38946574-34B29A67-C6DC-4D0A-BE26-DA0C46037F7AQ39400551-6427E498-77FD-4C28-AD16-EBD9B6912561Q43272828-52C45FBF-1F74-420E-8BCB-3D8BCAEB9057Q47993800-B196953D-8CF1-4E48-9FE9-9CDC7767498CQ48524454-B96127B4-7E13-4128-BFC1-5BA4499B8196Q48680730-50559E02-109F-48D8-9F22-8A739B36A31EQ48695155-080A52B8-8658-4096-B16E-502D8BD5F03EQ52105199-DB16C976-ACA8-40BB-9BFC-5B5C7E8027C5Q52123807-BE781927-6EA0-43FD-B86F-6C162A9BA529
P2860
Cerebral MRI abnormalities associated with vigabatrin therapy.
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Cerebral MRI abnormalities associated with vigabatrin therapy.
@ast
Cerebral MRI abnormalities associated with vigabatrin therapy.
@en
Cerebral MRI abnormalities associated with vigabatrin therapy.
@nl
type
label
Cerebral MRI abnormalities associated with vigabatrin therapy.
@ast
Cerebral MRI abnormalities associated with vigabatrin therapy.
@en
Cerebral MRI abnormalities associated with vigabatrin therapy.
@nl
prefLabel
Cerebral MRI abnormalities associated with vigabatrin therapy.
@ast
Cerebral MRI abnormalities associated with vigabatrin therapy.
@en
Cerebral MRI abnormalities associated with vigabatrin therapy.
@nl
P2093
P1433
P1476
Cerebral MRI abnormalities associated with vigabatrin therapy
@en
P2093
Ari Heffron
Elizabeth Gilles
Elizabeth Molloy-Wells
Joan A Conry
Louis G Vezina
Marcio Sotero de Menezes
Nancy J Elling
Phillip L Pearl
Raymond Ferri
Robert McCarter
P2860
P304
P356
10.1111/J.1528-1167.2008.01728.X
P577
2008-09-08T00:00:00Z